Brian Henick

@BHenickMD

Proud husband/father. Phase I, Thoracic+Head/Neck Med Onc @ColumbiaCancer @NYPHospital @ColumbiaMed. Editor @JCOPO_ASCO. Views my own ≠ advice.

Joined April 2018

555 Following 439 Followers 177 Posts

Latest posts 5

Brian Henick @BHenickMD Jul 17

We are excited to collaborate with @evolveimmune and other centers on this study, evaluating a new therapeutic target in squamous cancers. cancer.columbia.edu/cancer-types-c…

www.cancer.columbia.edu Phase I Clinical Trials & Experimental Therapeutics You'll have access to clinical trials for some of the most promising new immunotherapy and molecularly targeted treatments.

Herbert Irving Comprehensive Cancer Center @columbiacancer Jul 16

Squamous cell carcinomas were some of the first cancers to see approvals for immunotherapy, but less than 1 in 5 patients see a lasting benefit. A new clinical trial from @BHenickMD at @ColumbiaMed is testing a new drug designed to tackle this challenge. cancer.columbia.edu/news/targeting…

View quoted post on X

Brian Henick @BHenickMD Jun 17

Agreed, these clinical definitions are key to cut through the heterogeneity of patients with NSCLC who get exposed to ICI. Not all progression is the same, and “overcoming resistance” should be an increasingly precise effort ascopubs.org/doi/full/10.12…

ascopubs.org Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials:...

Adam J. Schoenfeld Verified account @AdamJSchoenfeld Jun 16

Important perspective led by @DDoroshow and the Lung-MAP team in @JCO_ASCO on defining primary vs acquired resistance to immune checkpoint inhibitors in NSCLC clinical trials.

Critical as we develop the next generation of post-ICI studies.

View quoted post on X

Brian Henick @BHenickMD Dec 27, 2024

Thank you to participating patients and their families on NCT02716038. On behalf of my co-authors, we are grateful to @jitcancer for the opportunity to publish our clinical update and translational analysis

Journal for ImmunoTherapy of Cancer Verified account @jitcancer Dec 27, 2024

New #JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings bit.ly/49TdeqN @BHenickMD @DrMarkAwad @BizarMd @JustinGainor @CatherineShuMD

View quoted post on X

Brian Henick @BHenickMD Oct 29, 2024

On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-del tumors at the
@EORTC - @theNCI - @AACR conference ir.ideayabio.com/2024-10-25-IDE… We are excited to offer this study to our patients recruit.cumc.columbia.edu/studyinfopage/…

ir.ideayabio.com IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and... ~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC patients 9 of 9 responses have confirmed by...

Brian Henick @BHenickMD Jul 19, 2024

Grateful for the opportunity to develop this exciting program with Dr. Marilyn Li and the #AACRGENIE team!
@columbiacancer

AACR @AACR Jul 18, 2024

AACR Project GENIE® held its Summer Summit this week in Philadelphia. Chaired by Brian Henick and Marilyn Li, the summit celebrated the 10th anniversary of the think tank convened by AACR Past-President @CharlesSawyers that launched this vital initiative.
#AACRGENIE @BHenickMD

View quoted post on X